In November 2020, the General Directorate of Common Portfolio of National Health System and Pharmacy Services published the Resolution on an agreement of the Commission of Benefits, Insurance, And Financing in relation to the proton therapy technique.
The key points of the agreement are provided below:
- The creation of an interdisciplinary committee in each autonomous community to evaluate each specific case of proton therapy is recommended
- General guidelines/criteria for proton therapy to be followed were developed
- Therapeutic indications for adults were agreed upon:
- Intraocular/uveal melanoma when brachytherapy is not indicated
- Chordoma and chondrosarcoma
- Primary paraspinal sarcoma when the radiation therapy dose exceeds tolerance medullary
- Therapeutic indications for children were agreed upon:
- Brain tumors
- Eye tumors
- Soft tissue sarcomas
- Ewing’s tumor
- Neuroblastoma
- The Autonomous Communities should send the data for each of the patients undergoing proton therapy semiannually to the General Sub-directorate of the Basic Package of Services of the National Health System
The full details in Spanish can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First, EU issues of both newsletters are available for download free-of-charge.